AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 22 - (NewsRx.com & NewsRx.net) -- BioCryst Pharmaceuticals, Inc., (BCRX) announced that patient enrollment is complete in the first phase III trial of once-a-day, orally administered peramivir (RWJ-270201), BioCryst's influenza neuraminidase inhibitor.
The multicenter, phase III clinical trial was completed in the United States during the 2001-2002 influenza season. BioCryst expects preliminary data from the trial will be available during the third quarter 2002.
The objective of the phase III trial is to assess the efficacy and safety of peramivir for the treatment of acute influenza A and influenza B infections in otherwise ...